We report a case of late-onset schizophrenia that required differentiation from a dementing disorder. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Motor and cognitive performance differed across PD and control groups. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Neurodegenerative disorders (NDDs), primarily alzheimer, dementia, parkinson, and rare NDD disease, present an escalating global health crisis, currently affecting over 55 million older adults worldwide. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A neuropathological study of Alzheimer type I (Alz I) and Alzheimer type II (Alz II) as well as Opalski (Opl) cells was performed serially on brain tissue from nine autopsied Wilson's disease (WD) cases. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The behavioural and mental health needs of people with PWS result from the interactions between biological vulnerabilities associated with having PWS and living in a changing and demanding environment. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
30/100
Frequently occurring copathology, most commonly with Alzheimer disease, leads to greater cognitive decline, increased likelihood of admission to a long-term care facility, and a higher risk of mortality. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Levodopa/carbidopa is the cornerstone treatment for Parkinson's disease (PD), but in patients with dysphagia, there are limited options for the routes of administration. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Chronic pain is defined as pain that persists or recurs for more than 3 months. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Apolipoprotein E-4 (APOE-4), serotonin transporter gene (SLC6A4), and single nucleotide polymorphisms (SNPs) of glucocerebrosidase (GBA) are some of the main altered genes in AD, PDD and DLB. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The present study investigated the frequency and distribution of TUNEL-positive neurons in brains of dementia with Lewy bodies (DLB) in comparison with those in brains of Alzheimer's disease (AD), Down syndrome (DS) and non-demented elderly persons. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A 34-year-old man developed three generalised seizures over a period of 2 weeks. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The diagnostic significance of tau proteins in cerebrospinal fluids (CSF) has been described in many cases of dementia of Alzheimer type (AD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Con el envejecimiento de la población general, el número de pacientes con epilepsia de inicio tardío crece constantemente. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Little is known about the chronic sequelae of isopropanol ingestion. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
BackgroundPathogenic variants in GCH1 have been associated with Parkinsons disease (PD), but the clinical phenotype and longitudinal disease course of GCH1-associated PD remain incompletely characterized. 5 key findings →
Design: longitudinal study Participants: 22,825 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Cognitive and behavioural impairment frequently accompanies motor decline in amyotrophic lateral sclerosis (ALS), with 15% of cases meeting the diagnostic criteria for frontotemporal dementia (FTD). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Impairment in the comprehension of morphosyntactic and transitivity information does not feature in current diagnostic guidelines for primary progressive aphasia (PPA) or Alzheimers Diseases (AD), despite research reporting delayed sensitivity or insensitivity of these clinical populations to these linguistic domains. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dopamine replacement therapy (DRT) alleviates motor symptoms in Parkinsons disease (PD) but can trigger hallucinations in a subset of patients, yet the neural basis of this selective vulnerability is unknown. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Greater baseline WMH burden was associated with differential longitudinal progression in converters across eleven clinical outcomes, including cognition, gait, and functional independence (all q<0.05). 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Gross brain findings help guide differential diagnosis, but their diagnostic value across major neurodegenerative diseases remains incompletely characterized. 5 key findings →
Participants: 5,613 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
IntroductionFrontotemporal lobar degeneration (FTLD) is a devastating disease that commonly results in early onset dementia, yet its rarity and heterogeneity limit large-scale research and clinical trials. 2 key findings →
Design: longitudinal study Participants: 567 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
16/100
Simulation results were benchmarked against real-world population estimates, over a wide range of demographic and genetic parameters. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
From across this tag
10 of the 1,021 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Pathology of Neurodegenerative Diseases
- Cognitive training in Parkinson disease: A systematic review and meta-analysis
- History of falls in Parkinson disease is associated with reduced cholinergic activity
- Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders
- Neuropathologic Correlates of Seizures in Patients With Alzheimer Disease and Dementia With Lewy Bodies
- Staging of brain pathology related to sporadic Parkinson’s disease
- Quantitative susceptibility mapping reveals differences between subtypes of Lewy body dementia
- Human ALS/FTD brain organoid slice cultures display distinct early astrocyte and targetable neuronal pathology
- Neuroimaging and plasma biomarker differences and commonalities in Lewy body dementia subtypes
- Dementia and survival in Parkinson disease: a 12-year population study
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →